WEREWOLF THERAPEUTICS, INC. Deferred Revenue, Revenue Recognized
WEREWOLF THERAPEUTICS, INC. (HOWL) reported Deferred Revenue, Revenue Recognized of $2.34 million for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-11.
Discontinued › Income Statement › Other Income
us-gaap:DeferredRevenueRevenueRecognized1 · last filed 2023-05-11
- WEREWOLF THERAPEUTICS, INC. deferred revenue, revenue recognized for the quarter ending 2023-03-31 was $2.34M.
- WEREWOLF THERAPEUTICS, INC. deferred revenue, revenue recognized for fiscal 2022 was $7.34M.
| Period end | Deferred Revenue, Revenue Recognized 3 month | Deferred Revenue, Revenue Recognized 6 month | Deferred Revenue, Revenue Recognized 9 month | Deferred Revenue, Revenue Recognized 12 month |
|---|---|---|---|---|
| 2023-03-31 | $2.34M 10-Q · filed 2023-05-11 | |||
| 2022-12-31 | $7.34M 10-K · filed 2023-03-23 | |||
| 2022-09-30 | $4.20M 10-Q · filed 2022-11-10 | |||
| 2022-06-30 | $1.93M 10-Q · filed 2022-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |